Pharmaceutical Suppositories Market Report 2026

The pharmaceutical suppositories market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.89 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of constipation and hemorrhoids, rising awareness of non-oral drug delivery, development of basic rectal and vaginal suppositories, growth in hospital and home care sectors, expansion of pharmaceutical manufacturing infrastructure.

The pharmaceutical suppositories market size is expected to see strong growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to advancements in personalized medicine, innovation in drug delivery technology, rising demand for herbal and natural products, growth in geriatric and pediatric care, adoption of temperature-stable formulations. Major trends in the forecast period include personalized dosage suppositories, natural and herbal suppository formulations, pediatric and geriatric suppository development, novel drug delivery mechanisms, temperature-stable and long shelf-life suppositories.

The increasing prevalence of diseases is expected to drive the growth of the pharmaceutical suppositories market. Disease prevalence is rising due to factors such as geography, climate, and insect-borne transmission of pathogens. Pharmaceutical suppositories provide an effective drug delivery method to treat a growing number of patients across various conditions. A pharmaceutical suppository is a small, cylindrical or conical dosage form that is inserted into the rectum, vagina, or urethra, where it melts or dissolves to release the active drug for therapeutic effect. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023, marking an 18% increase from 3,065,825 cases in 2022. This rising disease prevalence is therefore fueling the demand for pharmaceutical suppositories.

Key companies in the pharmaceutical suppositories market are focusing on developing complex formulations and obtaining regulatory approvals to enhance market access, affordability, and patient outcomes. For example, in August 2023, Zydus Lifesciences, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (USFDA) for Indomethacin suppositories with a Competitive Generic Therapy (CGT) designation. This designation accelerates the development of generic drugs with limited competition, ensuring affordability for patients. The advanced formulation promotes effective drug delivery and absorption, and Zydus was granted a 180-day exclusivity period, incentivizing further innovation while meeting high standards of quality, safety, and efficacy.

In April 2023, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences for $10.8 billion. This acquisition allows Merck to participate in Phase 2 trials for treatments for ulcerative colitis and Crohn’s disease using Prometheus’s monoclonal antibody therapies delivered via suppositories. Prometheus Biosciences, a US-based biotechnology company, specializes in developing precision therapies for immune-mediated diseases through innovative suppository formulations.

Major companies operating in the pharmaceutical suppositories market are Bayer AG, Pfizer Inc, Novartis International AG, Sanofi S.A., Intas Pharmaceuticals Ltd, Unither Pharmaceuticals, Cosette Pharmaceuticals Inc, Aenova Holding GmbH, Delpharm, Bliss GVS Pharma Ltd, JoinHub Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Divis Laboratories Ltd, Dr. Reddys Laboratories Ltd, Apollo Hospitals Enterprise Ltd, Torrent Pharmaceuticals Ltd, Chiesi Farmaceutici, CSPC Pharmaceutical Group, Esteve Química, Humanwell Healthcare (Group) Co, Jiangsu Hengrui Pharmaceutical, GlaxoSmithKline (GSK), Nordic Pharma Group, Phoenix Pharma Group, DocMorris, Medpex, AstraZeneca, Abbott Laboratories, Mylan, Zentiva, Teva Pharmaceutical Industries Ltd, AbbVie Inc, Apotex, EMS Pharma, Biolab Farmaceutica, Boehringer Ingelheim, JRS Pharma, Roquette, Odan Laboratories Ltd, Axantia, Kiara Health (Pty) Ltd, IBD Africa, Menarini Group, Padagis LLC.

North America was the largest region in the pharmaceutical suppositories market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical suppositories market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical suppositories market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pharmaceutical suppositories market by increasing the cost of imported raw materials and excipients, affecting production timelines and pricing strategies. Rectal and vaginal suppository segments, particularly in regions like Asia-Pacific and Europe where imports are significant, have been most impacted. While tariffs raise production costs, they also encourage local manufacturing and sourcing of pharmaceutical ingredients, potentially boosting regional production capacities and reducing dependence on imports.

The pharmaceutical suppositories market research report is one of a series of new reports that provides pharmaceutical suppositories market statistics, including pharmaceutical suppositories industry global market size, regional shares, competitors with a pharmaceutical suppositories market share, detailed pharmaceutical suppositories market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical suppositories industry. This pharmaceutical suppositories market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A pharmaceutical suppository is a small, solid medication that is inserted into the vagina or rectum and gradually dissolves at body temperature. Suppositories deliver active ingredients through mucous membranes to treat conditions such as constipation, inflammation, infections, or pain. They are particularly useful when oral administration is not feasible, such as during nausea, vomiting, or difficulty swallowing.

The main types of pharmaceutical suppositories include rectal suppositories, vaginal suppositories, urethral suppositories, and others. Rectal suppositories are designed for insertion into the rectum. The bases used include fatty, water-miscible, and emulsifying bases. These products are used across hospitals, clinics, nursing homes, homecare settings, and other healthcare environments.

The pharmaceutical suppositories market consists of sales of conventional suppositories, in vitro fertilization, and vardenafil. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.